(−)Deprenyl and (−)parafluorodeprenyl-treatment prevents age-related pigment changes in the substantia nigra. A TV-image analysis of neuromelanin
- 30 April 1992
- journal article
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 63 (2) , 157-163
- https://doi.org/10.1016/0047-6374(92)90061-h
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- The pharmacology of selegiline ((−)deprenyl). New aspectsActa Neurologica Scandinavica, 1989
- The Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's DiseaseScience, 1989
- Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm studyJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1985
- Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeysEuropean Journal of Pharmacology, 1984
- Deprenyl (selegiline): the history of its development and pharmacological actionActa Neurologica Scandinavica, 1983
- The possible mechanisms of action of (-)deprenyl in Parkinson's diseaseJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1978